Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Badri N. Vardarajan is active.

Publication


Featured researches published by Badri N. Vardarajan.


Science | 2015

De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies

Jason Homsy; Samir Zaidi; Yufeng Shen; James S. Ware; Kaitlin E. Samocha; Konrad J. Karczewski; Steven R. DePalma; David M. McKean; Hiroko Wakimoto; Josh Gorham; Sheng Chih Jin; John Deanfield; Alessandro Giardini; George A. Porter; Richard Kim; Kaya Bilguvar; Francesc López-Giráldez; Irina Tikhonova; Shrikant Mane; Angela Romano-Adesman; Hongjian Qi; Badri N. Vardarajan; Lijiang Ma; Mark J. Daly; Amy E. Roberts; Mark W. Russell; Seema Mital; Jane W. Newburger; J. William Gaynor; Roger E. Breitbart

Putting both heart and brain at risk For reasons that are unclear, newborns with congenital heart disease (CHD) have a high risk of neurodevelopmental disabilities. Homsy et al. performed exome sequence analysis of 1200 CHD patients and their parents to identify spontaneously arising (de novo) mutations. Patients with both CHD and neurodevelopmental disorders had a much higher burden of damaging de novo mutations, particularly in genes with likely roles in both heart and brain development. Thus, clinical genotyping of patients with CHD may help to identify those at greatest risk of neurodevelopmental disabilities, allowing surveillance and early intervention. Science, this issue p. 1262 Genotyping of children with congenital heart disease may identify those at high risk of neurodevelopmental disorders. Congenital heart disease (CHD) patients have an increased prevalence of extracardiac congenital anomalies (CAs) and risk of neurodevelopmental disabilities (NDDs). Exome sequencing of 1213 CHD parent-offspring trios identified an excess of protein-damaging de novo mutations, especially in genes highly expressed in the developing heart and brain. These mutations accounted for 20% of patients with CHD, NDD, and CA but only 2% of patients with isolated CHD. Mutations altered genes involved in morphogenesis, chromatin modification, and transcriptional regulation, including multiple mutations in RBFOX2, a regulator of mRNA splicing. Genes mutated in other cohorts examined for NDD were enriched in CHD cases, particularly those with coexisting NDD. These findings reveal shared genetic contributions to CHD, NDD, and CA and provide opportunities for improved prognostic assessment and early therapeutic intervention in CHD patients.


Blood Cells Molecules and Diseases | 2008

BCL11A is a major HbF quantitative trait locus in three different populations with β-hemoglobinopathies ☆

Amanda Sedgewick; Nadia Timofeev; Paola Sebastiani; Jason C.C. So; Edmond S. K. Ma; Li Chong Chan; Goonnapa Fucharoen; Supan Fucharoen; Cynara G. Barbosa; Badri N. Vardarajan; Lindsay A. Farrer; Clinton T. Baldwin; Martin H. Steinberg; David H.K. Chui

Increased HbF levels or F-cell (HbF containing erythrocyte) numbers can ameliorate the disease severity of beta-thalassemia major and sickle cell anemia. Recent genome-wide association studies reported that single nucleotide polymorphisms (SNPs) in BCL11A gene on chromosome 2p16.1 were correlated with F-cells among healthy northern Europeans, and HbF among Sardinians with beta-thalassemias. In this study, we showed that SNPs in BCL11A were associated with F-cell numbers in Chinese with beta-thalassemia trait, and with HbF levels in Thais with either beta-thalassemia or HbE trait and in African Americans with sickle cell anemia. Taken together, the data suggest that the functional motifs responsible for modulating F-cells and HbF levels reside within a 3 kb region in the second intron of BCL11A.


JAMA Neurology | 2011

A comprehensive genetic association study of Alzheimer disease in African Americans.

Mark W. Logue; Matthew Schu; Badri N. Vardarajan; Jacki Buros; Robert C. Green; Rodney C.P. Go; Patrick Griffith; Thomas O. Obisesan; Rhonna Shatz; Amy R. Borenstein; L. Adrienne Cupples; Kathryn L. Lunetta; M. Daniele Fallin; Clinton T. Baldwin; Lindsay A. Farrer

OBJECTIVES To evaluate the association of genetic variation with late-onset Alzheimer disease (AD) in African Americans, including genes implicated in recent genome-wide association studies of whites. DESIGN We analyzed a genome-wide set of 2.5 million imputed markers to evaluate the genetic basis of AD in an African American population. SUBJECTS Five hundred thirteen well-characterized African American AD cases and 496 cognitively normal African American control subjects. SETTING Data were collected from multiple sites as part of the Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study and the Henry Ford Health System as part of the Genetic and Environmental Risk Factors for Alzheimer Disease Among African Americans (GenerAAtions) Study. RESULTS Several significant single-nucleotide polymorphisms (SNPs) were observed in the region of the apolipoprotein E gene (APOE). After adjusting for the confounding effects of APOE genotype, one of these SNPs, rs6859 in PVRL2, remained significantly associated with AD (P = .0087). Association was also observed with SNPs in CLU, PICALM, BIN1, EPHA1, MS4A, ABCA7, and CD33, although the effect direction for some SNPs and the most significant SNPs differed from findings in data sets consisting of whites. Finally, using the African American genome-wide association study data set as a discovery sample, we obtained suggestive evidence of association with SNPs for several novel candidate genes. CONCLUSIONS Some genes contribute to AD pathogenesis in both white and African American cohorts, although it is unclear whether the causal variants are the same. A larger African American sample will be needed to confirm novel gene associations, which may be population specific.


Neurobiology of Aging | 2012

Identification of Alzheimer disease-associated variants in genes that regulate retromer function.

Badri N. Vardarajan; Sophia Y. Bruesegem; Michael E. Harbour; Peter St George-Hyslop; Matthew N.J. Seaman; Lindsay A. Farrer

The proteolytic processing of amyloid precursor protein (APP) to generate the neurotoxic amyloid β (Aβ) peptide is central to the pathogenesis of Alzheimer disease (AD). The endocytic system mediates the processing of APP by controlling its access to secretases that cleave APP. A key mediator of APP localization is SorL1-a membrane protein that has been genetically linked to AD. The retromer complex is a conserved protein complex required for endosome-to-Golgi retrieval of a number of physiologically important membrane proteins including SorL1. Based on the prior suggestion that endocytosis and retromer sorting pathways might be involved, we hypothesized that variants in other genes in this pathway might also modulate AD risk. Genetic association of AD with 451 polymorphisms in 15 genes encoding retromer or retromer-associated proteins was tested in a Caucasian sample of 8309 AD cases and 7366 cognitively normal elders using individual single nucleotide polymorphism (SNP)- and gene-based tests. We obtained significant evidence of association with KIAA1033 (VEGAS p = 0.025), SNX1 (VEGAS p = 0.035), SNX3 (p = 0.0057), and RAB7A (VEGAS p = 0.018). Ten KIAA1033 SNPs were also significantly associated with AD in a group of African Americans (513 AD cases, 504 control subjects). Findings with four significant SNX3 SNPs in the discovery sample were replicated in a community-based sample of Israeli-Arabs (124 AD cases, 142 control subjects). We show that Snx3 and Rab7A proteins interact with the cargo-selective retromer complex through independent mechanisms to regulate the membrane association of retromer and thereby are key mediators of retromer function. These data implicate additional AD risk genes in the retromer pathway and formally demonstrate a direct link between the activity of the retromer complex and the pathogenesis of AD.


Circulation Research | 2014

Increased Frequency of De Novo Copy Number Variants in Congenital Heart Disease by Integrative Analysis of Single Nucleotide Polymorphism Array and Exome Sequence Data

Joseph T. Glessner; Alexander G. Bick; Kaoru Ito; Jason Homsy; Laura Rodriguez-Murillo; Menachem Fromer; Erica Mazaika; Badri N. Vardarajan; Jeremy Leipzig; Steven R. DePalma; Ryan Golhar; Stephan J. Sanders; Boris Yamrom; Michael Ronemus; Ivan Iossifov; A. Jeremy Willsey; Matthew W. State; Jonathan R. Kaltman; Peter S. White; Yufeng Shen; Dorothy Warburton; Martina Brueckner; Christine E. Seidman; Elizabeth Goldmuntz; Bruce D. Gelb; Richard P. Lifton; Jonathan G. Seidman; Hakon Hakonarson; Wendy K. Chung

Rationale: Congenital heart disease (CHD) is among the most common birth defects. Most cases are of unknown pathogenesis. Objective: To determine the contribution of de novo copy number variants (CNVs) in the pathogenesis of sporadic CHD. Methods and Results: We studied 538 CHD trios using genome-wide dense single nucleotide polymorphism arrays and whole exome sequencing. Results were experimentally validated using digital droplet polymerase chain reaction. We compared validated CNVs in CHD cases with CNVs in 1301 healthy control trios. The 2 complementary high-resolution technologies identified 63 validated de novo CNVs in 51 CHD cases. A significant increase in CNV burden was observed when comparing CHD trios with healthy trios, using either single nucleotide polymorphism array (P=7×10−5; odds ratio, 4.6) or whole exome sequencing data (P=6×10−4; odds ratio, 3.5) and remained after removing 16% of de novo CNV loci previously reported as pathogenic (P=0.02; odds ratio, 2.7). We observed recurrent de novo CNVs on 15q11.2 encompassing CYFIP1, NIPA1, and NIPA2 and single de novo CNVs encompassing DUSP1, JUN, JUP, MED15, MED9, PTPRE SREBF1, TOP2A, and ZEB2, genes that interact with established CHD proteins NKX2-5 and GATA4. Integrating de novo variants in whole exome sequencing and CNV data suggests that ETS1 is the pathogenic gene altered by 11q24.2-q25 deletions in Jacobsen syndrome and that CTBP2 is the pathogenic gene in 10q subtelomeric deletions. Conclusions: We demonstrate a significantly increased frequency of rare de novo CNVs in CHD patients compared with healthy controls and suggest several novel genetic loci for CHD.


Annals of Neurology | 2011

SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk

Christiane Reitz; Shinya Tokuhiro; Lorraine N. Clark; Christopher Conrad; Jean Paul Vonsattel; Lili Naz Hazrati; András Palotás; Raphael Lantigua; Martin Medrano; Ivonne Z. Jimenez-Velazquez; Badri N. Vardarajan; Irene Simkin; Jonathan L. Haines; Margaret A. Pericak-Vance; Lindsay A. Farrer; Joseph H. Lee; Ekaterina Rogaeva; Peter St George-Hyslop; Richard Mayeux

Sorting mechanisms that cause the amyloid precursor protein (APP) and the β‐secretases and γ‐secretases to colocalize in the same compartment play an important role in the regulation of Aβ production in Alzheimers disease (AD). We and others have reported that genetic variants in the Sortilin‐related receptor (SORL1) increased the risk of AD, that SORL1 is involved in trafficking of APP, and that underexpression of SORL1 leads to overproduction of Aβ. Here we explored the role of one of its homologs, the sortilin‐related VPS10 domain containing receptor 1 (SORCS1), in AD.


Annals of Neurology | 2015

Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci

Badri N. Vardarajan; Mahdi Ghani; Amanda Kahn; Stephanie Sheikh; Christine Sato; Sandra Barral; Joseph H. Lee; Rong Cheng; Christiane Reitz; Rafael Lantigua; Dolly Reyes-Dumeyer; Martin Medrano; Ivonne Z. Jimenez-Velazquez; Ekaterina Rogaeva; Peter St George-Hyslop; Richard Mayeux

To detect rare coding variants underlying loci detected by genome‐wide association studies (GWAS) of late onset Alzheimer disease (LOAD).


Annals of Neurology | 2015

Coding mutations in SORL1 and Alzheimer disease.

Badri N. Vardarajan; Yalun Zhang; Joseph H. Lee; Rong Cheng; Christopher Bohm; Mahdi Ghani; Christiane Reitz; Dolly Reyes-Dumeyer; Yufeng Shen; Ekaterina Rogaeva; Peter St George-Hyslop; Richard Mayeux

Common single nucleotide polymorphisms in the SORL1 gene have been associated with late onset Alzheimer disease (LOAD), but causal variants have not been fully characterized nor has the mechanism been established. The study was undertaken to identify functional SORL1 mutations in patients with LOAD.


Annals of Neurology | 2015

Rare coding mutations identified by sequencing of Alzheimer's disease GWAS loci

Badri N. Vardarajan; Mahdi Ghani; Amanda Kahn; Stephanie Sheikh; Christine Sato; Sandra Barral; Joseph H. Lee; Rong Cheng; Christiane Reitz; Rafael Lantigua; Dolly Reyes-Dumeyer; Martin Medrano; Ivonne Z. Jimenez-Velazquez; Ekaterina Rogaeva; Peter St George-Hyslop; Richard Mayeux

To detect rare coding variants underlying loci detected by genome‐wide association studies (GWAS) of late onset Alzheimer disease (LOAD).


Alzheimers & Dementia | 2014

Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans

Mark W. Logue; Matthew Schu; Badri N. Vardarajan; John J. Farrell; David A. Bennett; Joseph D. Buxbaum; Goldie S. Byrd; Nilufer Ertekin-Taner; Denis A. Evans; Tatiana Foroud; Alison Goate; Neill R. Graff-Radford; M. Ilyas Kamboh; Walter A. Kukull; Jennifer J. Manly; Jonathan L. Hainesm; Richard Mayeuxl; Margaret A. Pericak-Vancen; Gerard D. Schellenbergo; Kathryn L. Lunettab; Clinton T. Baldwina; M. Daniele Fallinp; Lindsay A. Farrer

Less is known about the genetic basis of Alzheimers disease (AD) in African Americans (AAs) than in non‐Hispanic whites.

Collaboration


Dive into the Badri N. Vardarajan's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jonathan L. Haines

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge